Live tape
Top 8, mentions 7d12,037SPCX2,527 mentions▲ +0.08GOOGL1,950 mentions▲ +0.02META1,905 mentions▲ +0.04TSLA1,807 mentions▲ +0.05NFLX1,015 mentions▲ +0.02QQQ1,008 mentions▲ +0.05AMZN922 mentions▲ +0.06NVDA903 mentions▲ +0.07

Equity · Healthcare

ARWR

NASDAQ

Arrowhead Pharmaceuticals (ARWR)

$58.02 +0.03% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 23, 2026
Price · Chart
64 sessions
$90 $50 27 Jul 23 Oct

The line runs $86 on 27 July through $58.02 on 23 October, on a scale from $50 to $90. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 64 sessions, 27 Jul – 23 Oct 2026
Market cap $8.2B
52-week range $36.81 – $89.61
Avg volume 124.5K

as of Oct 23, 2026

Arrowhead Pharmaceuticals (ARWR) insider trades

SEC Form 4 · last 90 days · newest reported trade 18 Aug 2026

In the 90 days to 25 Oct 2026, Arrowhead Pharmaceuticals insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 1 Oct 2025, show no open-market purchase.

Open-market buys 0
Open-market sells 2
Net sold $1.19M
Non-trade filings 0
Date Insider Type Shares Value
18 Aug 2026 OLUKOTUN ADEOYE Y Director Sell 2,000 $174K
18 Aug 2026 PERRY MICHAEL S Director Sell 11,600 $1.01M

Arrowhead Pharmaceuticals (ARWR) reported financials

SEC EDGAR XBRL SEC EDGAR

Arrowhead Pharmaceuticals reported revenue of $829.4M for the fiscal year ended 30 Sep 2025. Net income over the same period was −$1.6M.

Figure Reported Period
Revenue $829.4M 30 Sep 2025 fiscal year
Net income −$1.6M 30 Sep 2025 fiscal year
Diluted EPS −$0.01 30 Sep 2025 fiscal year
Total assets $2.1B 30 Jun 2026 at period end
Total equity $465.5M 30 Jun 2026 at period end

Arrowhead Pharmaceuticals (ARWR) earnings

SEC EDGAR

Arrowhead Pharmaceuticals last reported earnings on 30 Jun 2026 for Q3 2026, with EPS of −$1.36; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q3 2026 −$1.36 —
31 Mar 2026 Q2 2026 −$0.93 —
31 Dec 2025 Q1 2026 $0.22 —
30 Sep 2025 FY 2025 −$0.01 —
30 Jun 2025 Q3 2025 −$1.26 —
31 Mar 2025 Q2 2025 $2.75 —
31 Dec 2024 Q1 2025 −$1.39 —
30 Sep 2024 FY 2024 −$5.00 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Arrowhead Pharmaceuticals (ARWR) institutional holders (13F)

SEC Form 13F SEC EDGAR

9 of the 45 institutional funds we track reported a Arrowhead Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined $467.1M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) 1,992,783 $162.4M
Fisher Asset Management Held (±25%) −14.0% shares 957,691 $78.1M
Two Sigma Investments Added +1,521.8% shares 580,609 $47.3M
Balyasny Asset Management Added +128.1% shares 470,754 $38.4M
Renaissance Technologies Trimmed −54.8% shares 468,921 $38.2M
D. E. Shaw & Co. Trimmed −63.5% shares 431,560 $35.2M
Millennium Management New position 329,337 $26.8M
Marshall Wace Added +69.9% shares 305,031 $24.9M
AQR Capital Management Held (±25%) +18.9% shares 198,842 $15.8M
Bridgewater Associates Exited

Arrowhead Pharmaceuticals (ARWR) fails-to-deliver

SEC CNS data SEC

On 28 Sep 2026, 8,174 shares of Arrowhead Pharmaceuticals failed to deliver (about $539K).

Settlement date Shares failed Notional % of shares out
28 Sep 2026 8,174 $539K 0.006%

Congressional trades in Arrowhead Pharmaceuticals (ARWR)

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in Arrowhead Pharmaceuticals is a sale by Daniel S. Goldman (house, NY), dated 31 Jan 2023.

Date Member Type Amount
31 Jan 2023 filed 24 Feb 2023 Daniel S. Goldman house · Democrat–NY Sale $1K–$15K

Arrowhead Pharmaceuticals (ARWR): frequently asked questions

From live data

Have Arrowhead Pharmaceuticals insiders bought or sold shares recently?

In the 90 days to 25 Oct 2026, Arrowhead Pharmaceuticals insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 1 Oct 2025, show no open-market purchase.

How many institutions hold Arrowhead Pharmaceuticals?

9 of the 45 institutional funds we track reported a Arrowhead Pharmaceuticals position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Arrowhead Pharmaceuticals had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Arrowhead Pharmaceuticals is dated 28 Sep 2026, when 8,174 shares failed to deliver.

When did Arrowhead Pharmaceuticals last report earnings?

Arrowhead Pharmaceuticals last reported earnings on 30 Jun 2026 for Q3 2026, with EPS of −$1.36; no next date is announced in SEC filings yet.

What exchange is Arrowhead Pharmaceuticals listed on?

Arrowhead Pharmaceuticals trades on NASDAQ under the ticker ARWR.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SEC EDGARValuation computed from SEC EDGAR filings